DOI 10.1016/j.ijbiomac.2025.148934
DCs-targeted full-cell nanovaccine based on chitosan oligosaccharide self-assembled with ganoderma lucidum polysaccharide for enhancing tumor immunotherapy.
Аннотация
Tumor vaccines, designed to deliver immunogenic antigens and initiate tumor-specific immune responses, hold significant promise for cancer prevention and therapy. However, their efficacy remains limited by the inherently low immunogenicity of tumor antigens and inefficient antigen presentation. To address these challenges, we developed a self-assembled polysaccharide-based nanovaccine platform (CGT) for treating orthotopic, recurrent, and metastatic tumors in murine models. In vitro and in vivo studies demonstrated that CGT effectively delivers tumor antigens to dendritic cells (DCs), enhances DC maturation, and activates antigen-specific immune responses. Notably, in orthotopic, recurrent, and metastatic 4 T1 breast cancer models, CGT exhibited robust anti-tumor efficacy, significantly inhibiting primary tumor growth and suppressing distant lung metastasis. This work provides a novel strategy to amplify tumor vaccine immunogenicity and establishes a versatile platform for achieving potent anti-tumor immunity against complex malignancies.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.